IL-5

Rat IgG2a

Recombinant Human IL-5

The JES1-5A10 monoclonal antibody specifically binds to the human Interleukin-5 (IL-5). IL-5 is a cytokine that is also known as T-cell replacing factor (TRF), Eosinophil differentiation factor (EDF), and B cell differentiation factor I. IL-5 is produced by T cells, mast cells, and eosinophils. IL-5 controls the generation, differentiation, activation and localization of eosinophils. IL-5 also activates and promotes the differentiation of basophils. IL-5 plays an important role in regulating cell-mediated immunity against parasitic infections and some tumors. High level IL-5 production is involved in some allergic diseases including asthma. IL-5 exerts its biological effects by binding to and signaling through high-affinity heterodimeric IL-5 receptors comprised of transmembrane IL-5 receptor alpha (IL-5Rα, aka, CD125) and beta common (βc, aka, CD131) chains. The βc chain serves as the common signaling subunit for the IL-5 receptor heterodimer as well as for the heterodimeric IL-3 and GM-CSF receptors. The immunogen used to generate the JES1-5A10 hybridoma was recombinant human IL-5. The JES1-5A10 antibody has been reported to cross react with IL-5 from rhesus monkey. This is a neutralizing antibody. This antibody is routinely tested by ELISA Detection. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.

JES1-5A10 The JES1-5A10 monoclonal antibody specifically binds to the human Interleukin-5 (IL-5). IL-5 is a cytokine that is also known as T-cell replacing factor (TRF), Eosinophil differentiation factor (EDF), and B cell differentiation factor I. IL-5 is produced by T cells, mast cells, and eosinophils. IL-5 controls the generation, differentiation, activation and localization of eosinophils. IL-5 also activates and promotes the differentiation of basophils. IL-5 plays an important role in regulating cell-mediated immunity against parasitic infections and some tumors. High level IL-5 production is involved in some allergic diseases including asthma. IL-5 exerts its biological effects by binding to and signaling through high-affinity heterodimeric IL-5 receptors comprised of transmembrane IL-5 receptor alpha (IL-5Rα, aka, CD125) and beta common (βc, aka, CD131) chains. The βc chain serves as the common signaling subunit for the IL-5 receptor heterodimer as well as for the heterodimeric IL-3 and GM-CSF receptors. The immunogen used to generate the JES1-5A10 hybridoma was recombinant human IL-5. The JES1-5A10 antibody has been reported to cross react with IL-5 from rhesus monkey. This is a neutralizing antibody. This antibody is routinely tested by ELISA Detection. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.

Rat IgG2a

克隆 JES1-5A10 (RUO)

0.5 mg/ml

ELISA Detection (Routinely Tested)

Human (QC Testing)

IL-5

Aqueous buffered solution containing ≤0.09% sodium azide.

研发参考(5) 1. Abrams JS, Roncarolo MG, Yssel H, Andersson U, Gleich GJ, Silver JE. Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev. 1992; 127:5-24. (Clone-specific: ELISA). 2. Abrams JS, Silver JE, Van Dyke RE, Gleich GI. Eosinophil-active cytokines in human disease: development and use of monoclonal antibodies to IL-3, IL-5 and GMCSF. In: Gleich GJ and Kay AB, ed. Eosinophils in Allergy and Inflammation. New York: Dekker; 1994:133-157. 3. Butterfield JH, Leiferman KM, Abrams J, et al. Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood. 1992; 79(3):688-692. (Clone-specific: ELISA). 4. Denburg JA, Silver JE, Abrams JS. Interleukin-5 is a human basophilopoietin: induction of histamine content and basophilic differentiation of HL-60 cells and of peripheral blood basophil-eosinophil progenitors. Blood. 1991; 77(7):1462-1468. (Biology). 5. Limaye AP, Abrams JS, Silver JE, et al. Interleukin-5 and the posttreatment eosinophilia in patients with onchocerciasis. J Clin Invest. 1991; 88(4):1418-1421. (Clone-specific: ELISA).